The FDA has approved a new medication for pancreatic cancer patients called daraxonrasib, a once-daily pill that blocks RAS proteins and has been shown to double patient survival time when compared to standard chemotherapy treatment.Read more: https://t.co/Em6Pb1TqRi📸: Sarah Silbiger via Getty Images ...

Regulatory Approvals & Product Development - Revolution Medicines secured US regulatory approval for its pancreatic cancer drug daraxonrasib [1] - The drug represents the first medicine to target one of the key molecular causes of the disease [1]